NCT00413101View on ClinicalTrials.gov

A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

Not specified

Study Completion Date

March 31, 2008

Conditions
Anemia
Interventions
DRUG

epoetin beta [NeoRecormon]

At a dose to achieve and maintain an Hb level of 120-135g/L

Trial Locations (1)

21000

Novi Sad

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00413101 - A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease. | Biotech Hunter | Biotech Hunter